CL vs IBIO · P/E 34, rev $20.38B vs rev $100.0K
Colgate-Palmolive Company (CL) versus iBio, Inc. Common Stock (IBIO) — a side-by-side from cached financials, not a winner call.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
Latest reported CL revenue for 2025-12-31 was $20.38B. Net income was $2.13B. Revenue was up 1.4% from 2024-12-31 to 2025-12-31. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
CL currently screens at market cap $70.88B and trailing P/E 34.3. IBIO currently screens at market cap $13.4M.
Not investment advice. Open the CL and IBIO stock pages for the full models.
Not investment advice.